Literature DB >> 20063086

[Testosterone and infertility].

S Kliesch1.   

Abstract

About 15% of men and women in their reproductive years remain childless; in 50% of cases the reasons can be found in the male partner. It is important to define as exactly as possible the reasons for infertility to select those men who can be treated by a causal treatment option and to find the optimum treatment strategy. While FSH is the key hormone for intact spermatogenesis, testosterone as an important modifier of quantitative normal sperm production may sometimes be underestimated. Exogenous substitution with testosterone will suppress spermatogenesis and is thus not indicated in hypogonadal males with hypogonadism and infertility at the same time. In males with normal to elevated gonadotrophins and symptomatic testosterone deficiency, treatment is difficult and evidence-based recommendations are missing. The situation in males presenting with secondary hypogonadotropic hypogonadism exhibiting one of the clearly defined and treatable reasons of male infertility is totally different. To stimulate the gonadal function in secondary hypogonadal patients wishing to father a child, pulsatile GnRH or subcutaneous gonadotrophin treatment are used. They stimulate both testosterone production and spermatogenesis. After the end of successful fertility treatment, substitution is continued by exogenous testosterone treatment with oral, transdermal or intramuscular physiological preparations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20063086     DOI: 10.1007/s00120-009-2195-x

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  11 in total

1.  Valvular heart disease and the use of dopamine agonists for Parkinson's disease.

Authors:  Renzo Zanettini; Angelo Antonini; Gemma Gatto; Rosa Gentile; Silvana Tesei; Gianni Pezzoli
Journal:  N Engl J Med       Date:  2007-01-04       Impact factor: 91.245

2.  Success of testicular sperm extraction [corrected] and intracytoplasmic sperm injection in men with Klinefelter syndrome.

Authors:  Jonathan D Schiff; Gianpiero D Palermo; Lucinda L Veeck; Marc Goldstein; Zev Rosenwaks; Peter N Schlegel
Journal:  J Clin Endocrinol Metab       Date:  2005-08-30       Impact factor: 5.958

3.  Treatment of severe oligospermia with human chorionic gonadotropin/human menopausal gonadotropin: a placebo-controlled, double blind trial.

Authors:  U A Knuth; W Hönigl; M Bals-Pratsch; G Schleicher; E Nieschlag
Journal:  J Clin Endocrinol Metab       Date:  1987-12       Impact factor: 5.958

Review 4.  [Genetics of male infertility].

Authors:  F Tüttelmann; J Gromoll; S Kliesch
Journal:  Urologe A       Date:  2008-12       Impact factor: 0.639

Review 5.  Klinefelter's syndrome.

Authors:  Fabio Lanfranco; Axel Kamischke; Michael Zitzmann; Eberhard Nieschlag
Journal:  Lancet       Date:  2004 Jul 17-23       Impact factor: 79.321

6.  High efficacy of gonadotropin or pulsatile gonadotropin-releasing hormone treatment in hypogonadotropic hypogonadal men.

Authors:  S Kliesch; H M Behre; E Nieschlag
Journal:  Eur J Endocrinol       Date:  1994-10       Impact factor: 6.664

7.  Valvular heart disease and the use of cabergoline for the treatment of prolactinoma.

Authors:  Neil Herring; Cezary Szmigielski; Harald Becher; Niki Karavitaki; John A H Wass
Journal:  Clin Endocrinol (Oxf)       Date:  2009-01       Impact factor: 3.478

Review 8.  Hyperprolactinemia and prolactinomas.

Authors:  Tatiana Mancini; Felipe F Casanueva; Andrea Giustina
Journal:  Endocrinol Metab Clin North Am       Date:  2008-03       Impact factor: 4.741

Review 9.  Genetic insights into human isolated gonadotropin deficiency.

Authors:  Ericka Barbosa Trarbach; Leticia Gontijo Silveira; Ana Claudia Latronico
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

10.  Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases.

Authors:  D Büchter; H M Behre; S Kliesch; E Nieschlag
Journal:  Eur J Endocrinol       Date:  1998-09       Impact factor: 6.664

View more
  6 in total

Review 1.  [Drug therapy options for oligoasthenoteratozoospermia syndrome].

Authors:  M Trottmann; F M Köhn; M Dickmann; C G Stief; A J Becker
Journal:  Urologe A       Date:  2011-01       Impact factor: 0.639

2.  Long-term follow-up of fertility and pregnancy in autoimmune diseases after autologous haematopoietic stem cell transplantation.

Authors:  G Massenkeil; T Alexander; O Rosen; B Dörken; G Burmester; A Radbruch; F Hiepe; R Arnold
Journal:  Rheumatol Int       Date:  2016-08-13       Impact factor: 2.631

3.  Use of Exogenous Testosterone for the Treatment of Male Factor Infertility: A Survey of Nigerian Doctors.

Authors:  Olufunmilade Akinfolarin Omisanjo; Stephen Odunayo Ikuerowo; Moruf Adekunle Abdulsalam; Sheriff Olabode Ajenifuja; Khadijah Adebisi Shittu
Journal:  Int J Reprod Med       Date:  2017-08-29

4.  Effect of Wuzi Yanzong on Reproductive Hormones and TGF-β1/Smads Signal Pathway in Rats with Oligoasthenozoospermia.

Authors:  Zhuo Yang; Xi Zhang; Zhimin Chen; Changjiang Hu
Journal:  Evid Based Complement Alternat Med       Date:  2019-04-16       Impact factor: 2.629

5.  Discovery of methylpyrimidine ring-fused diterpenoid analogs as a novel testosterone synthesis promoter.

Authors:  Jie Bai; Jia Xie; Li-Ting Wang; Yajing Xing; Qian-Ru Jiang; Fan Yang; Jie Tang; Zhengfang Yi; Wen-Wei Qiu
Journal:  RSC Adv       Date:  2019-03-27       Impact factor: 4.036

6.  Effects of the yangjing capsule extract on steroidogenesis and apoptosis in mouse leydig cells.

Authors:  Dalin Sun; Yugui Cui; Baofang Jin; Xindong Zhang; Xiaoyu Yang; Chao Gao
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-13       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.